Patience is not one of my virtues.

I was reminded of this as I began my Christmas shopping five days earlier than normal. I waited 20 minutes to get a smoothie at our local fast food restaurant. It is because of waits like these and my lack of patience that I normally do my Christ­mas shopping on Christmas Eve day.

There is little traffic, the stores are not crowded, the lines at the gift wrap­ping kiosks are not long, and one doesn’t have to wait for 30 minutes to get …

My husband Daniel and I love visiting New York City at Christmas time. No other city seems to decorate quite so well, and we find all the festivity is just what the doctor ordered to get us in the holiday spirit.

We made our familiar pilgrimage to New York earlier this month, and we visited a major department store to see the holiday windows and all the decorations they had hanging inside.

The store’s theme this year is Believe in the Magic of Christmas, and while I understand that it’s …

As the 2015 holiday season reaches it peak, all of us here at The Myeloma Beacon would like to thank you, our readers and members of the myeloma community worldwide, for giving us the greatest gift possible: your time. 

We appreciate your coming to The Beacon and reading our articles, letting us know your thoughts about them, and sharing your experiences and helping one another in our discussion forum.

The holiday season is a time of many different traditions. It also is a busy time, when it is easy to lose …

Those of you who have been following my story remember how carefully my wife Pattie and I weighed the pros and cons before deciding I would proceed with a salvage autologous stem cell transplant.

The transplant this summer worked so well that my myeloma specialist strongly recommended that we repeat it this fall.

There was just a touch of measurable multiple myeloma left. Why not stick with a therapy that was working? Hit my myeloma hard while it’s down.

Once again, we agreed with his logic. Just as I began …

• Natco to Acquire License to Sell Generic Lena­lido­mide in the U.S. Without Volume Limitation commencing in late Jan­u­ary­, 2026
• License Will Also Provide Natco With a Volume-Limited Entry Beginning in March, 2022 with Anticipated Mid-Single-Digit Percentage Of Capsules Sold In the First 12 Months, Anticipated to Increase Gradually Each Year

{{image}}Summit, NJ (Press Release) – Celgene Corpo­ra­tion (NASDAQ: CELG) today announced the settle­ment of lit­i­ga­tion with Natco Pharma Ltd. of India, Natco’s U.S. partner, Arrow Inter­na­tional Limited, and Arrow’s parent com­pany, Watson Laboratories, Inc. (a wholly-owned sub­sid­i­ary of Allergan plc) relating to patents for REVLIMID^® (lena­lido­mide).

As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Natco from mar­ket­ing generic lena­lido­mide before the expiration of …

I have noticed a difference, one I may have mentioned earlier, but one which is becoming more pronounced in recent months. Given my lab results, my myeloma seems to be slipping back into remission. I am grate­ful for that. But after 11 years of the disease and treatments, my body is wear­ing down. To borrow from Atul Gawande’s Being Mortal, the night brigade has been out there busily taking down the perimeter defenses.

As a result, I have an increased awareness of time slipping through my fingers. I am like …

Boudry, Switzerland, and Tokyo (Press Release) – Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that REVLIMID^® (lena­lido­mide), a cancer medi­cine that is admin­istered orally, has been granted full market­ing authori­za­tion by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in com­bi­na­tion with dexa­meth­a­sone as a treat­ment for patients newly diag­nosed with multiple myeloma. This market­ing authori­za­tion expands upon the approval of REVLIMID in 2010 for the treat­ment of patients with re­lapsed or refractory multiple myeloma.

“The approval of REVLIMID as an option for …